ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

RENE Reneuron Group Plc

3.05
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.05 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 530k -5.41M -0.0946 -0.32 1.74M
Reneuron Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker RENE. The last closing price for Reneuron was 3.05p. Over the last year, Reneuron shares have traded in a share price range of 2.95p to 10.25p.

Reneuron currently has 57,173,760 shares in issue. The market capitalisation of Reneuron is £1.74 million. Reneuron has a price to earnings ratio (PE ratio) of -0.32.

Reneuron Share Discussion Threads

Showing 4976 to 4997 of 8900 messages
Chat Pages: Latest  200  199  198  197  196  195  194  193  192  191  190  189  Older
DateSubjectAuthorDiscuss
15/3/2016
09:52
New to me was that at 12 minutes onwards he says the new Exosome has another possible use as they unexpectedly found it causes cancer tumour "collapse" after 18 days leaving just "cellular debris" and they have repeated this in vivo. It seems to be "programming cancer cells to adopt a normal cycle of cell death."



Not many people seem to be aware of this other new treatment but it is another possible multi billion market on top of stroke and RP.

He says they will trial this in humans in 2016. If it only takes three weeks to be effective they should have early results very quickly. British Biotech went from 50p to over £24 on hope for its cancer drug and its worth a bet Rene's will really work.

noteworthy5
15/3/2016
09:42
noteworthy5

Rene MAY turn out to be big winner for shareholders, me included, but the reason the shares are circa 3p now is because there is NO GUARANTEE that any one of their product evaluations will actually do what the company hopes they will do. It's a better investment than speculatively drilling for oil or mining for diamonds...but it's still a speculation.

dickbush
15/3/2016
09:39
The RP treatment can get to market quickly says Michael Hunt after 5 min 30 sec
noteworthy5
15/3/2016
08:47
Being promoted elsewhere I see while locked in holders attempt to exit, not a good combination IMO.
mike111d
15/3/2016
08:18
Rene's fast tracked RP treatment could be filed for market in 2018. Seems like they have another winner on top of the stroke treatments. This is going to be worth billions.
noteworthy5
15/3/2016
07:48
Could have been the US medics..... ever since watching ER I don't trust them.
small crow
15/3/2016
07:39
Who says companies do not leak news to insiders ?
norbus
15/3/2016
07:12
Good news. Let's hope it goes well.
small crow
14/3/2016
19:40
They raised £68.4 million in a Placing last August and the Interim results in December said they had cash, cash equivalents and bank deposits at 30/9/2015 of £72.28 million. On 11/1/2016 they were awarded a further £2.1 million grant from Innovate UK to advance the exosome nanomedicine platform.

This has mega bagger written all over it. If as seems possible they have one or two effective treatments for stroke the sales will be multi bllions as most people either gets a stroke, heart attack or cancer and the market is global.

noteworthy5
14/3/2016
17:11
Noteworthy, tell us about this recent placing for which there is apparently no RNS.
When was it and how much was raised?

horneblower
14/3/2016
16:19
noteworthy5 Shhhhhh; keep in to yourself.
norbus
14/3/2016
16:08
i said what i think. RENE could be the next big winner. £70m cash on the books after a recent successful placing, broker consensus uprated to 10p, chairman recently upped his holding, and key Phase 2 stroke results and Phase 1 limb ishaemia results due in H1 2016. If as seems likely from data already released they have one or two effective treatments for stroke and its effects this will be worth billions. basically most people will either get stroke, heart attack or cancer meaning the market is global and as big as it gets.
noteworthy5
14/3/2016
15:02
Someone called Noteworthy5 is flooding the boards (well 5 or 6 posts) regarding a new placing and recent chairman share purchase.
I can find no rns's or news about this. However...I do like the chart...
and have bought 200k at 3.375p.

horneblower
14/3/2016
14:37
SP moving slowly but surely- some news due?
stewart_25
16/2/2016
13:06
No - still can't see it.
small crow
16/2/2016
09:54
If you PI's want transparency? sign this petition!
ps0u3165
16/2/2016
09:24
small crow
As similar as I am to Lionel Messi? We can both wear football kit.

iomhere
16/2/2016
09:12
Our CTXcryo product, US patents just applied, for could be a major factor in commercialising the breakthrough outlined in the Mirror...hopefully Woodford will have our management knocking on their door.
hlp_4u
16/2/2016
09:11
Similar in what way?
small crow
16/2/2016
09:08
Front page of the Mirror today....immunotherapy breakthrough... 94 percent cure rate using technology similar to RENE
hlp_4u
10/2/2016
20:33
ReNeuron CFO Michael Hunt will be presenting to investors at the Proactive One2One Forum in Manchester on the evening of 24th February 2016. To register to attend, please click here:
aim_trader
08/2/2016
23:18
link



cheers
ft ft

ftangftang
Chat Pages: Latest  200  199  198  197  196  195  194  193  192  191  190  189  Older

Your Recent History

Delayed Upgrade Clock